1. Vaccine Therapies for Cancer: Then and Now

   • Michael A. Morse
   • William R. Gwin III
   • Duane A. Mitchell

   Review Article Open access 29 January 2021 Pages: 121 - 152

   

2. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma

   • Lin Liu
   • Shukui Qin
   • Yu Zhang

   Review Article 02 February 2021 Pages: 153 - 163

   

3. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

   • Ying Cheng
   • Yong He
   • Suresh S. Ramalingam

   Original Research Article Open access 05 February 2021 Pages: 165 - 176

   

4. A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers

   • Jian Zhang
   • Nong Yang
   • Xichun Hu

   Original Research Article Open access 25 January 2021 Pages: 177 - 187

   

5. Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma

   • Wataru Fukuokaya
   • Takahiro Kimura
   • Shin Egawa

   Original Research Article 05 January 2021 Pages: 189 - 196

   

6. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors

   • Maximilian Gassenmaier
   • Max M. Lenders
   • Nikolaus B. Wagner

   Original Research Article Open access 08 February 2021 Pages: 197 - 205

   

7. Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis

   • Chi-Lu Chiang
   • Cheng-Chia Lee
   • Chao-Hua Chiu

   Original Research Article 10 February 2021 Pages: 207 - 214

   

8. Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC

   • Jiacong Wei
   • Pei Meng
   • Anke van den Berg

   Original Research Article Open access 19 February 2021 Pages: 215 - 226

   

9. BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?

   • Vanessa Wong
   • Margaret Lee
   • Peter Gibbs

   Original Research Article 18 February 2021 Pages: 227 - 236

   

10. Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab

    • Yoshiyasu Kono
    • Yasuhiro Choda
    • Hiroyuki Okada

    Short Communication 21 January 2021 Pages: 237 - 248

    

11. Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison

    • Andrea Casadei-Gardini
    • Toshifumi Tada
    • Alessandro Cucchetti

    Short Communication 27 February 2021 Pages: 249 - 254